You are here
Virtual Meeting
The 2013 Annual Meeting Virtual Meeting is now available. All sessions are live.
Virtual Meeting is a collection of videos recorded during ASCO's meetings and symposia. Access to these feature-rich presentations are included with registration for meeting attendees for desktop and personal device access. Non-attendees may purchase Virtual Meeting at the ASCO Bookstore. ASCO members receive a 20% discount from a code provided during the purchase.
Activation
Meeting attendees do not need to activate Virtual Meeting. Non-attendees, please activate Virtual Meeting before first use at asco.org/activate.
Most Viewed Virtual Meeting Presentations
- Discussion (2012 ASCO Annual Meeting)
- Discussion (2012 ASCO Annual Meeting)
- Adjuvant Chemotherapy in 2013: Which Patient? What Regimen? (2013 ASCO Annual Meeting)
- Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. (2013 ASCO Annual Meeting)
- Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. (2013 ASCO Annual Meeting)
- First-in-human phase I study of CetuGEX, a novel anti-EGFR monoclonal antibody (mAb) with optimized glycosylation and antibody dependent cellular cytotoxicity. (2013 ASCO Annual Meeting)
- B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology (2013 ASCO Annual Meeting)
- Clinical activity and safety of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). (2013 ASCO Annual Meeting)
- Overcoming Resistance to Cancer Drug Therapy (2013 ASCO Annual Meeting)
- Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). (2013 ASCO Annual Meeting)